STERIS (STE) Stock Forecast & Price Target

$224.16 +3.07 (+1.39%)

As of 04/14/2025 03:58 PM Eastern

STERIS - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 5 Analyst Ratings

Sell
0

Hold
1

Buy
4

Based on 5 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for STE.

Consensus Price Target

$258.75
15.43% Upside

According to the 5 analysts' twelve-month price targets for STERIS, the average price target is $258.75. The highest price target for STE is $265.00, while the lowest price target for STE is $240.00. The average price target represents a forecasted upside of 15.43% from the current price of $224.16.

Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

STE Analyst Ratings Over Time

Type	Current Forecast 4/15/24 to 4/15/25	1 Month Ago 3/16/24 to 3/16/25	3 Months Ago 1/16/24 to 1/15/25	1 Year Ago 4/16/23 to 4/15/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$258.75	$258.75	$262.50	$239.60
Forecasted Upside	15.43% Upside	13.97% Upside	27.02% Upside	19.05% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

STERIS Stock vs. The Competition

Type	STERIS	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	15.43% Upside	24,971.66% Upside	25.85% Upside
News Sentiment Rating	Positive News See Recent STE News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/10/2025	JMP Securities 2 of 5 stars	David Turkaly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$265.00 ➝ $265.00	+20.94%
4/7/2025	Needham & Company LLC 2 of 5 stars	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/6/2025	Stephens 4 of 5 stars	Jacob Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$240.00 ➝ $240.00	+7.49%
2/3/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Bednar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$260.00 ➝ $265.00	+21.26%
9/3/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$255.00 ➝ $265.00	+9.11%
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$225.00 ➝ $215.00	+5.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:17 AM ET.

Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, April 7, 2025. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

Here are some ways that investors could benefit from investing in STERIS plc:

STERIS plc has a strong market capitalization of $20.94 billion, indicating a robust financial position and potential for growth.
The company reported a quarterly earnings per share (EPS) of $2.32, which, despite missing the consensus estimate slightly, reflects solid profitability in the medical equipment sector.
With a current stock price of $213.16, STERIS plc is positioned within a 12-month range of $197.82 to $248.24, suggesting potential for price appreciation.
STERIS plc has a healthy current ratio of 2.13, indicating that it has more than twice the amount of current assets compared to its current liabilities, which is a sign of good short-term financial health.
The company has a dividend yield of 1.07%, providing investors with a return on investment through regular dividend payments, which can be attractive for income-focused investors.

STERIS
Bear Case

Investors should be bearish about investing in STERIS plc for these reasons:

STERIS plc's P/E ratio stands at 45.26, which is relatively high, suggesting that the stock may be overvalued compared to its earnings, potentially limiting future price growth.
The company recently experienced a slight miss in earnings expectations, which could indicate challenges in meeting market forecasts and may affect investor confidence.
Despite a strong market position, the medical equipment sector can be highly competitive and subject to regulatory changes, which may impact STERIS plc's operations and profitability.
The debt-to-equity ratio of 0.32, while not excessively high, indicates that the company does carry some debt, which could pose risks if market conditions change.
Recent changes in institutional holdings, including a significant reduction by LPL Financial LLC, may signal a lack of confidence among large investors, which could influence market perception negatively.

STE Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $258.75, with a high forecast of $265.00 and a low forecast of $240.00.
: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" STE shares.
: According to analysts, STERIS's stock has a predicted upside of 15.43% based on their 12-month stock forecasts.
: STERIS has been rated by research analysts at JMP Securities, Needham & Company LLC, Piper Sandler, and Stephens in the past 90 days.
: Analysts like STERIS less than other "medical" companies. The consensus rating score for STERIS is 2.80 while the average consensus rating score for "medical" companies is 2.82. Learn more on how STE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:STE) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Stock Forecast & Price Target